Search results
Results from the WOW.Com Content Network
The principal for obstetric management of COVID-19 include rapid detection, isolation, and testing, profound preventive measures, regular monitoring of fetus as well as of uterine contractions, peculiar case-to-case delivery planning based on severity of symptoms, and appropriate post-natal measures for preventing infection.
Nirmatrelvir/ritonavir has been evaluated in the treatment of COVID‑19 in standard-risk individuals in the EPIC-SR trial. [51] [53] This study did not achieve its primary goal of reducing time to sustained alleviation of COVID‑19 symptoms (treatment: 13 days (95% CI 12–15 days); placebo: 13 days (95% CI 11–14 days)).
The research that led to nirmatrelvir began in March 2020, when Pfizer formally launched a project at its Cambridge, Massachusetts site to develop antiviral drugs for treating COVID-19. [15] In July 2020, Pfizer chemists were able to synthesize nirmatrelvir for the first time. [ 15 ]
COVID-19: Merck & Co. viral RNA polymerase inhibitor Moroxydine: Influenza Nelfinavir: HIV Nirmatrelvir/ritonavir (Paxlovid) COVID-19: Pfizer: 3C-like protease inhibitor (Nirmatrelvir) / inhibition of metabolism of nirmatrelvir (ritonavir) Nevirapine: HIV non-nucleoside reverse transcriptase inhibitor: Nitazoxanide: Broad-spectrum antiviral ...
Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November ...
As the new coronavirus spreads, doctors are seeing a pattern emerge in the way people are responding to the disease. People at first will experience mild symptoms like a light cough or headache.
In August 2020, the NIAID started the Adaptive COVID‑19 Treatment Trial 3 (ACTT 3) to evaluate the safety and efficacy of a treatment regimen consisting of remdesivir plus interferon beta-1a for hospitalized adults who have a laboratory-confirmed SARS-CoV-2 infection with evidence of lung involvement, including a need for supplemental oxygen ...
Coronavirus disease 2019 (COVID-19) Yes: Coxsackie B virus: Coxsackie B virus infection Enterovirus infection is diagnosed mainly via serological tests such as ELISA and from cell culture. There is no well-accepted treatment for the Coxsackie B group of viruses. Under research [10] PRNP: Creutzfeldt–Jakob disease (CJD) No Crimean-Congo ...